NZ Lung Cancer Research Review Issue 21

In this issue:
  -  Nivolumab plus chemotherapy in resectable disease
  -  Trastuzumab deruxtecan in HER2-mutant NSCLC
  -  Optimal duration of ICI therapy for NSCLC
  -  PPIs and the efficacy of EGFR-TKIs
  -  PPIs and the efficacy of ICIs
  -  Nivolumab plus ipilimumab in advanced NSCLC
  -  COVID-19 vaccine in patients with thoracic cancer
  -  Segmentectomy vs lobectomy in small-sized NSCLC
  -  CT screening lung cancer stage shift and survival
  -  Low-dose aspirin and incidence of lung cancer

Please login below to download this issue (PDF)

Subscribe